Last updated: 2026-09-22 21:51:00. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Immunic, Inc. (IMUX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $10.82, with a market capitalization of $144.90M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $5.06 to $17.43. This page covers its latest market performance, valuation, price trends and company information.
$144.90M | |
$10.95 | |
$289.90 | |
$5.06 | |
$10.83 | |
409.06K | |
220.80K | |
-- | |
$17.43 | |
$5.06 | |
-- | |
-- |
Immunic, Inc. (IMUX) is trading at $11.09 in after-hours trading as of 2026-09-22 21:37:00, up 2.38% ($0.26) from the regular-session close of $10.83.
After-hours trading shows how investors are pricing IMUX after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Immunic, Inc. (IMUX) moved from $11.42 to $10.82, representing a decline of 5.25% ($0.60).
The stock traded between $10.03 and $11.95 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 364.98 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 46.6%
IMUX is currently trading at $10.82, placing it 46.6% of the way from its 52-week low of $5.06 to its 52-week high of $17.43. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 95 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Immunic, Inc. (IMUX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.